Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Recurrence 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 34Cyclophosphamide 34Peripheral Blood Stem Cell Transplantation 23Busulfan 22Mycophenolic Acid 21Cyclosporine 20Whole-Body Irradiation 19Tacrolimus 18Antilymphocyte Serum 18Melphalan 16Filgrastim 16Radiotherapy 15Methotrexate 14fludarabine 12Cord Blood Stem Cell Transplantation 12Methylprednisolone 10Cytarabine 10Etoposide 8sargramostim 6Granulocyte Colony-Stimulating Factor 5Cyclosporins 5Alemtuzumab 4thymoglobulin 3merphos 3Tretinoin 3Thiotepa 3Thalidomide 3Sirolimus 3Rituximab 3Leucovorin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × darinaparsin × Classical hematology × Clear all
NCT00592046 2012-07-19

A Phase I Trial of ZIO-101 in Hematologic Cancers

Alaunos Therapeutics

Phase 1 Completed
12 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡